Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 1999
Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.
Epistemonikos ID: cad1e50fd78f1b05ea2f297838a3fdb453c80986
First added on: May 03, 2024